XML 21 R14.htm IDEA: XBRL DOCUMENT
v3.26.1

Collaboration and License Agreements | 3 Months Ended
--- | ---
Mar. 31, 2026
Collaboration And License Agreements [Abstract] |
Collaboration and License Agreements | 6. Collaboration and License Agreements Amgen On May 8, 2023, the Company entered into a Collaboration Agreement (the Amgen Agreement) with Amgen Inc. (Amgen) to identify antigens recognized by T cells in patients with Crohn’s disease in accordance with a research plan. Under the terms of the Amgen Agreement, Amgen will retain all global development and commercialization rights, as well as an option to expand the collaboration to include target discovery for ulcerative colitis, under certain pre-specified terms. The proceeds from the Amgen Agreement include an upfront payment of $30 million, which was collected in July 2023. In addition, the Company is eligible to earn success-based milestone payments of over $500 million, based upon the achievement of certain clinical development and commercial milestones, as well as tiered single-digit royalty payments on net sales of products developed from the collaboration, subject to reductions set forth in the Amgen Agreement. The Company concluded that Amgen meets the definition of a customer, as the Company is delivering research and development activities and a license of intellectual property. The Company identified performance obligations for research and development activities, the license, data reporting and participation in joint steering and research committees, which were determined to be a single combined performance obligation due to the services and licenses being highly interrelated. For a certain time period during the term of the Amgen Agreement, Amgen has an option to add targets to the collaboration for payments specified in the agreement. Pursuant to the Amgen Agreement, the option for Amgen to select additional targets and to license, develop, and commercialize targets is not a performance obligation at the outset as these are customer options that do not represent material rights. The Company looked to the promises in the arrangement to determine the method of recognition that best depicted the transfer of the services and the satisfaction of the combined performance obligations. The Company concluded that the performance of the research services over the expected research term was the predominant promise within the performance obligation. The Company will recognize the revenue associated with the performance obligation using an input method. The method of measuring progress towards delivery of the services incorporates actual internal and external costs incurred, relative to total internal and external costs expected to be incurred to satisfy the performance obligation. Changes in estimates of total internal and external costs expected to be incurred are recognized in the period of change as a cumulative catch-up adjustment. As costs are incurred, the Company will recognize revenue over time. At this time, it is estimated that the research term will be approximately three years. The Company determined the $30.0 million upfront payment to be the entirety of the consideration to be included in the transaction price as of the onset of the arrangement. The option to add additional targets was not included in the transaction price as they were assessed to be improbable at this time. The potential milestone and royalty payments that the Company is eligible to receive were also excluded from the transaction price, as all milestone and royalty amounts were fully constrained based on the assessed probability of achievement. The Company will continue to assess the probability of the option to add additional targets and the probability of milestone achievement throughout the research term and will adjust the consideration in the contract accordingly. The $30.0 million up-front payment was invoiced in June 2023 and was fully collected in July 2023. During the three months ended March 31, 2026 and 2025, the Company recognized $1.0 million and $2.2 million, respectively, of revenue associated with the Amgen Agreement. As of March 31, 2026, the Company recorded $1.6 million of deferred revenue which is classified as short-term.

X
- Definition Collaboration and license agreements. + References No definition available. + Details
Name: | tcrx_CollaborationAndLicenseAgreementsAbstract
Namespace Prefix: | tcrx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative and license arrangement disclosure. + References No definition available. + Details
Name: | tcrx_CollaborativeAndLicenseArrangementDisclosureTextBlock
Namespace Prefix: | tcrx_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration